Technical Analysis for ARGX - argenx SE
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
115.25 | -2.26% | -2.66 |
ARGX closed down 2.26 percent on Friday, October 18, 2019, on 78 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| See historical ARGX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | -2.26% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.26% | |
| Narrow Range Bar | Range Contraction | -2.26% | |
| Stochastic Reached Overbought | Strength | -2.26% | |
| Weak + Overbought | Other | -2.26% | |
| Gapped Up | Strength | -2.26% | |
| Overbought Stochastic | Strength | -2.26% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Diseases Rheumatoid Arthritis Acute Myeloid Leukemia Myelodysplastic Syndrome Dyslipidemia Hematological Cancers Treatment Of Autoimmune Diseases Myasthenia Gravis Janus Kinase Inhibitor Tolerx Treatment Of Hematological Cancers
Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Diseases Rheumatoid Arthritis Acute Myeloid Leukemia Myelodysplastic Syndrome Dyslipidemia Hematological Cancers Treatment Of Autoimmune Diseases Myasthenia Gravis Janus Kinase Inhibitor Tolerx Treatment Of Hematological Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 5 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ARGX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 150.92 |
| 52 Week Low | 71.48 |
| Average Volume | 153,287 |
| 200-Day Moving Average | 125.9569 |
| 50-Day Moving Average | 124.7474 |
| 20-Day Moving Average | 113.755 |
| 10-Day Moving Average | 112.433 |
| Average True Range | 3.3682 |
| ADX | 46.79 |
| +DI | 20.0549 |
| -DI | 33.929 |
| Chandelier Exit (Long, 3 ATRs ) | 117.9854 |
| Chandelier Exit (Short, 3 ATRs ) | 116.5946 |
| Upper Bollinger Band | 121.726 |
| Lower Bollinger Band | 105.784 |
| Percent B (%b) | 0.59 |
| BandWidth | 14.014329 |
| MACD Line | -2.8698 |
| MACD Signal Line | -4.18 |
| MACD Histogram | 1.3103 |
| Fundamentals | Value |
|---|---|
| Market Cap | 3.1 Billion |
| Num Shares | 26.9 Million |
| EPS | -1.27 |
| Price-to-Earnings (P/E) Ratio | -90.75 |
| Price-to-Sales | 15.41 |
| Price-to-Book | 3.49 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 121.66 | ||||
| Resistance 3 (R3) | 121.81 | 119.83 | 120.59 | ||
| Resistance 2 (R2) | 119.83 | 118.20 | 119.75 | 120.23 | |
| Resistance 1 (R1) | 117.54 | 117.19 | 116.55 | 117.39 | 119.88 |
| Pivot Point | 115.56 | 115.56 | 115.07 | 115.48 | 115.56 |
| Support 1 (S1) | 113.27 | 113.93 | 112.28 | 113.12 | 110.62 |
| Support 2 (S2) | 111.29 | 112.92 | 111.21 | 110.27 | |
| Support 3 (S3) | 109.00 | 111.29 | 109.91 | ||
| Support 4 (S4) | 108.85 |
